ReviewCurrent cardiology reports2026
Medication Non-Adherence in Resistant Hypertension: Detection, Drivers, and Practical Solutions.
Review in Current cardiology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewMost patients with hypertension cannot reach goal blood pressure with lifestyle modification alone, so hypertension control relies heavily on patients taking medications as prescribed. This review synthesizes recent literature on the role of medication non-adherence in apparent resistant hypertension, with attention to the definition of non-adherence, who is at risk, how it is detected, what it costs patients, and how clinicians can address it. RECENT
findingsWhen patients with apparent resistant hypertension undergo objective therapeutic drug monitoring, 25 to 80% are found to be non-adherent, and a substantial minority have no detectable drug at all. Neither clinicians nor patients reliably identify non-adherence by gestalt or self-report. Single-pill combinations consistently improve adherence and persistence relative to free-equivalent combinations, and in observational studies are associated with better cardiovascular outcomes. New pharmacologic agents that target the aldosterone and endothelin pathways produce substantial blood pressure reduction in true resistant hypertension but are not yet widely available, strengthening the case for confirming adherence before intensification of pharmacotherapy. Confirming adherence is a key initial step in the workup of apparent resistant hypertension. The weight of the evidence suggests that blood pressure reduction in this setting requires lowering barriers to adherence: simplifying regimens, lowering costs, and pairing objective measurement with non-judgmental conversation.
Indexed as
Identifiers
42640394What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.